Trial Profile
INCB018424 in the Treatment of Cutaneous Lichen Planus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2022
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Lichen planus
- Focus Therapeutic Use
- 01 Aug 2022 Results published in the Journal of Investigative Dermatology
- 25 Apr 2021 Primary endpoint (lesion count) has been met, as per results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
- 25 Apr 2021 Primary endpoint (modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS)) has been met, as per results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.